Lexaria Bioscience Corp (LEXX)

$1.06 -0.04 (-3.64%)
Market Cap 25.34M
Revenue (ttm) 460,000.00
Net Income (ttm) -5.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,260.87%
Debt to Equity Ratio 0.00
Volume 166,300
Avg Vol 684,590
Day's Range N/A - N/A
Shares Out 22.23M
Stochastic %K 51%
Beta 0.71
Analysts Strong Sell
Price Target $5.33

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH i...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
Smitty5150
Smitty5150 Nov. 14 at 9:20 PM
$LEXX that better be the last of those crooked SOB's
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:23 PM
$LEXX Still waiting on Invenomic who is our largest shareholder- second largest Murchinson held steady at 400k shares
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:22 PM
$LEXX State Street increased by 9%
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:21 PM
$LEXX Geode Capital mgmt increased holdings by 9%
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:20 PM
$LEXX TD increased position by 15% in Q3
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:19 PM
$LEXX Great news for investors that Sabby is gone 🍻
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:17 PM
$LEXX Sabby investment fully out of stock https://fintel.io/so/us/lexx
0 · Reply
MCAUL0898
MCAUL0898 Nov. 14 at 6:33 PM
$LEXX it’s been a long hold. That’s all I’m saying. Hopefully these guys can actually execute something of value at some point and recoup the painful journey in getting here. I’ve lost well over $100K and they still don’t have enough money to make it through all of next year. Pump it as you like, it’s a poor show with years of promised potential and whilst it appears a needed product, the burden is on us idiots with our hard earned cash to pay for the what if.
2 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 6:10 PM
$LEXX No one is listening to Scoobydoo anymore anyways
0 · Reply
Boston7452
Boston7452 Nov. 14 at 5:57 PM
$LEXX That is not true at all and Im speaking from experience. Stocks can trade at whatever price during discussions even after disclosed R&D. Its BS no doubt but it happens. All depends on the narrative that is being driven and the motivation behind it.
3 · Reply
Latest News on LEXX
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Nov 12, 2025, 9:10 AM EST - 2 days ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Provides Strategic Update

Oct 9, 2025, 9:20 AM EDT - 5 weeks ago

Lexaria Bioscience Corp. Provides Strategic Update

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 29, 2025, 4:30 PM EDT - 6 weeks ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 7 weeks ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Sep 19, 2025, 11:20 AM EDT - 2 months ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Aug 27, 2025, 9:20 AM EDT - 2 months ago

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 14, 2025, 9:20 AM EDT - 3 months ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Aug 6, 2025, 9:20 AM EDT - 3 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 3 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 3 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jul 23, 2025, 9:25 AM EDT - 4 months ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Jun 23, 2025, 9:15 AM EDT - 5 months ago

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 11, 2025, 9:05 AM EDT - 5 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria Attending BIO International Convention

Jun 5, 2025, 9:20 AM EDT - 5 months ago

Lexaria Attending BIO International Convention

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025, 9:00 AM EDT - 6 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 28, 2025, 4:15 PM EDT - 7 months ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 7 months ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 23, 2025, 9:10 AM EDT - 7 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 8 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 8 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Mar 18, 2025, 9:15 AM EDT - 8 months ago

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Mar 18, 2025, 9:15 AM EDT - 8 months ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Feb 27, 2025, 8:00 AM EST - 9 months ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Feb 24, 2025, 8:00 AM EST - 9 months ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 20, 2025, 8:00 AM EST - 9 months ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Feb 11, 2025, 8:00 AM EST - 9 months ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Feb 6, 2025, 9:40 AM EST - 10 months ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria Releases Annual Letter from the CEO

Jan 30, 2025, 9:15 AM EST - 10 months ago

Lexaria Releases Annual Letter from the CEO

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Jan 15, 2025, 9:20 AM EST - 10 months ago

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Jan 14, 2025, 9:10 AM EST - 10 months ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 19, 2024, 9:05 AM EST - 11 months ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

Dec 18, 2024, 9:25 AM EST - 11 months ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dec 17, 2024, 9:10 AM EST - 11 months ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Dec 9, 2024, 9:10 AM EST - 1 year ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Nov 26, 2024, 9:20 AM EST - 1 year ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Nov 25, 2024, 9:00 AM EST - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Nov 20, 2024, 9:05 AM EST - 1 year ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Nov 14, 2024, 9:10 AM EST - 1 year ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Nov 13, 2024, 9:20 AM EST - 1 year ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Nov 7, 2024, 9:15 AM EST - 1 year ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 24, 2024, 9:10 AM EDT - 1 year ago

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 22, 2024, 9:20 AM EDT - 1 year ago

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 15, 2024, 8:25 AM EDT - 1 year ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Lexaria Updates Current GLP-1 Market

Oct 8, 2024, 9:20 AM EDT - 1 year ago

Lexaria Updates Current GLP-1 Market

Lexaria Appoints Michael Shankman as Chief Financial Officer

Oct 1, 2024, 9:25 AM EDT - 1 year ago

Lexaria Appoints Michael Shankman as Chief Financial Officer

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

Sep 27, 2024, 9:20 AM EDT - 1 year ago

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

Lexaria Releases Strategic Letter from the Outgoing CEO

Sep 5, 2024, 10:00 AM EDT - 1 year ago

Lexaria Releases Strategic Letter from the Outgoing CEO

Lexaria Welcomes Industry Veteran as New CEO

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Lexaria Welcomes Industry Veteran as New CEO

Smitty5150
Smitty5150 Nov. 14 at 9:20 PM
$LEXX that better be the last of those crooked SOB's
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:23 PM
$LEXX Still waiting on Invenomic who is our largest shareholder- second largest Murchinson held steady at 400k shares
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:22 PM
$LEXX State Street increased by 9%
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:21 PM
$LEXX Geode Capital mgmt increased holdings by 9%
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:20 PM
$LEXX TD increased position by 15% in Q3
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:19 PM
$LEXX Great news for investors that Sabby is gone 🍻
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 8:17 PM
$LEXX Sabby investment fully out of stock https://fintel.io/so/us/lexx
0 · Reply
MCAUL0898
MCAUL0898 Nov. 14 at 6:33 PM
$LEXX it’s been a long hold. That’s all I’m saying. Hopefully these guys can actually execute something of value at some point and recoup the painful journey in getting here. I’ve lost well over $100K and they still don’t have enough money to make it through all of next year. Pump it as you like, it’s a poor show with years of promised potential and whilst it appears a needed product, the burden is on us idiots with our hard earned cash to pay for the what if.
2 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 6:10 PM
$LEXX No one is listening to Scoobydoo anymore anyways
0 · Reply
Boston7452
Boston7452 Nov. 14 at 5:57 PM
$LEXX That is not true at all and Im speaking from experience. Stocks can trade at whatever price during discussions even after disclosed R&D. Its BS no doubt but it happens. All depends on the narrative that is being driven and the motivation behind it.
3 · Reply
wa7ermelon
wa7ermelon Nov. 14 at 5:55 PM
$LEXX Although I do think the MTA is Novo Nordisk, it would probably be better if it was Eli Lilly 🚀
0 · Reply
wa7ermelon
wa7ermelon Nov. 14 at 5:29 PM
$LEXX @Shubeedoo I don't think any of us will be complaining if pharmco is Eli Lilly or Pfizer 🚀
1 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 5:24 PM
$LEXX Just remember - just like some post bullish things for a stock because they are long, some also post bearish things because they want cheaper prices. There truly is no other motive than that. In the past you could have totally tried to trade this but I think that ship has sailed. Too much at risk to miss a multi bagger on news vs try to scalp for 10%. Goodluck to the bears 🤡
0 · Reply
wa7ermelon
wa7ermelon Nov. 14 at 5:19 PM
$LEXX It looks like we have some naive posters on here that cannot comprehend why many of us believe that Novo Nordisk are most likely the the unknown pharmco. It really is not that difficult to add 2 + 2 together. Even if it isn't Novo, it is still some other Global Pharma in the GLP-1 space. We have had a great update the other day on MTA extension yet these negative posters still find something to cry about 😂
0 · Reply
DW65
DW65 Nov. 14 at 5:07 PM
$LEXX who is this Pharmoco company? Are they just a testing lab or a potential buyer?
1 · Reply
Shubeedoo
Shubeedoo Nov. 14 at 5:01 PM
$LEXX Please Tito
0 · Reply
Titosrbija
Titosrbija Nov. 14 at 3:16 PM
$LEXX attention shuelbee you may trigger some millionaires with that statement
1 · Reply
Shubeedoo
Shubeedoo Nov. 14 at 2:49 PM
$LEXX Really tired of hearing that NVO is most likely all over LEXX, probably being attacked. If there have been any discussions, a meeting, anything between LEXX and NVO, this would not be a $1 stock.
1 · Reply
Turbofueled
Turbofueled Nov. 14 at 2:42 PM
$LEXX GLP-1 is the most talked about in the Pharma sector!! $LEXX will be apart of this! Get on Board!! $NVO $PFE $MRK SIDE EFFECT REDUCTION NEEDED! https://www.foxnews.com/health/glp-1-weight-loss-medications-linked-improved-cancer-survival-certain-patients.amp
0 · Reply
paolo73
paolo73 Nov. 14 at 1:41 PM
$LEXX Even today the market is crap, the Nasdaq will go down by 2%... and if we go down slightly like yesterday it is not the company's responsibility but that of this embarrassing political class... both Republicans and Democrats, both right and left throughout the West and the results are visible... I hope that the next bubble, which will be that of AI, bursts after June so that we are already out of this market of madmen
0 · Reply
Makingmillions192
Makingmillions192 Nov. 14 at 12:43 PM
$LEXX We’re pretty fortunate to be in this industry right now because it looks like there is a big rotation going on in the markets. And healthcare looks to be one of the areas where cash is flowing too. Really couldn’t pick a better time for the perform storm for this thing to finally blow up.
0 · Reply
AceSantoro
AceSantoro Nov. 14 at 12:07 PM
$LEXX new shorts underwater
0 · Reply